Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice

Background: Immune checkpoint inhibitors have transformed clinical oncology. However, their use is limited as response is observed in only ~20–50% of patients. Previously, we demonstrated that treating CT26 tumor-bearing mice with ultra-high-concentration gaseous nitric oxide (UNO) followed by tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Confino, Hila, Sela, Yogev, Epshtein, Yana, Malka, Lidor, Goldshtein, Matan, Chaisson, Selena, Lisi, Steve, Avniel, Amir, Monson, Jedidiah Mercer, Dirbas, Frederick M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605471/
https://www.ncbi.nlm.nih.gov/pubmed/37887283
http://dx.doi.org/10.3390/cells12202439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605471/
https://www.ncbi.nlm.nih.gov/pubmed/37887283
http://dx.doi.org/10.3390/cells12202439

Ejemplares similares